KIORA PHARMACEUTICALS, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $16.0M | $0 | $0 | $12.1K | $2.7M | $1.7M | $407.5K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $10.8M | $7.8M | $4.0M | $5.4M | $3.6M | $5.4M | $8.1M | $10.3M |
| SG&A Expense | $5.7M | $5.5M | $4.7M | $5.3M | $4.7M | $4.4M | $4.4M | $4.6M |
| Operating Income | $-12.8M | $4.5M | $-12.6M | $-14.2M | $-6.9M | $-7.0M | $-10.8M | $-14.6M |
| Operating Margin | — | 28.2% | — | — | -56,960.5% | -260.6% | -656.3% | -3,572.5% |
| Interest Expense | — | — | $11.1K | $6.9K | $4.2K | $325 | $1.0K | $1.2K |
| Pretax Income | $-12.1M | $5.7M | $-12.4M | $-14.0M | $-6.8M | $-7.0M | $-10.7M | $-14.6M |
| Income Tax Expense | $-1.3M | $2.1M | $90.3K | $-192.6K | $12.1K | $95.4K | $86.0K | $-1.3M |
| Net Income | $-10.8M | $3.6M | $-12.5M | $-13.8M | $-6.9M | $-7.1M | $-10.8M | $-13.2M |
| Net Margin | — | 22.4% | — | — | -56,901.7% | -264.2% | -654.2% | -3,243.5% |
| EPS (Basic) | $-2.60 | $0.93 | $-3.03 | $-2.38 | $-0.06 | $-0.09 | $-0.19 | $-0.04 |
| EPS (Diluted) | $-2.64 | $0.87 | $-3.03 | $-2.38 | $-0.06 | $-0.09 | $-0.19 | $-0.04 |
| Shares Outstanding (Basic) | 4.2M | 3.9M | 4.3M | 5.8M | 110.2M | 97.9M | 72.9M | 414.2M |
| Shares Outstanding (Diluted) | 4.1M | 4.1M | 4.3M | 5.8M | 110.2M | 97.9M | 72.9M | 414.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |